February 2017

WEP Clinical and MendeliKABS Inc. enter exclusive Named Patient distribution agreement for MDK-Nitisinone

WEP Clinical, a global pharmaceutical and services company, and MendeliKABS Inc., a Canadian pharmaceutical company dedicated to the treatment of rare diseases, announce an exclusive Named Patient agreement to commercialise MDK-Nitisinone (nitisinone), a drug for [...]

By WEP|2022-12-05T15:15:16+00:00February 17th, 2017|News|

The importance of Real World Data

Upcoming US legislation, known as the 21st Century Cures Act, will incorporate more of the patient experience into drug development. There will be a focus on structured collection of data from patients about the personal [...]

By WEP|2021-03-15T11:42:31+00:00February 2nd, 2017|Big Pharma|